CRBP Corbus Pharmaceuticals Holdings Inc.

1.9
-0.06  -3%
Previous Close 1.96
Open 1.97
52 Week Low 1.75
52 Week High 9.78
Market Cap $155,253,055
Shares 81,712,134
Float 66,210,468
Enterprise Value $105,278,695
Volume 33,024,113
Av. Daily Volume 4,155,945
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Lenabasum
Cystic Fibrosis
Phase 2b
Phase 2b
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Lenabasum (resunab) - DETERMINE
Dermatomyositis
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Resunab - RESOLVE-1
Systemic Sclerosis
Phase 3
Phase 3
Phase 3 top-line data did not meet endpoints - September 8, 2020.
CRB-4001
Nonalcoholic steatohepatitis (NASH)
Phase 1
Phase 1
Phase 1 trial to commence in 2021.
Anabasum (Resunab)
Systemic lupus erythematosus (SLE)
Phase 2
Phase 2
Phase 2 enrollment to be completed late-2020 / early-2021.

Latest News

    • Topline data showed no significant differences in the primary and secondary endpoints when comparing lenabasum to placebo, both added to background drug therapy
    • Unprecedented improvement was observed in subjects on placebo added to background drug therapy, achieving median ACR CRISS score of 0.887
    • 84% of enrolled subjects were receiving background immunosuppressive drugs, reflecting recent trends in clinical practice
    • Lenabasum treatment was safe and well-tolerated in this study with no new safety signals observed
    • Further analyses of data are underway, and results will be presented at upcoming medical conferences
    • Lenabasum clinical trials in cystic fibrosis, dermatomyositis and systemic lupus erythematosus are ongoing
    • Company to host conference call…
    • Topline data showed no significant differences in the primary and secondary endpoints when comparing lenabasum to placebo, both added to background drug therapy
    • Unprecedented improvement was observed in subjects on placebo added to background drug therapy, achieving median ACR CRISS score of 0.887
    • 84% of enrolled subjects were receiving background immunosuppressive drugs, reflecting recent trends in clinical practice
    • Lenabasum treatment was safe and well-tolerated in this study with no new safety signals observed
    • Further analyses of data are underway, and results will be presented at upcoming medical conferences
    • Lenabasum clinical trials in cystic fibrosis, dermatomyositis and systemic lupus erythematosus are ongoing
    • Company to host conference call and webcast today, September 8, 2020 at 8:30 a.m. ET

    Norwood, MA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced topline results from the 52-week Phase 3 RESOLVE-1 study of lenabasum in patients with diffuse cutaneous systemic sclerosis (SSc). SSc is a rare and life-threatening multi-system autoimmune disease for which there are currently no U.S. Food and Drug Administration (FDA)-approved treatments for overall disease.

    Topline data showed no significant differences in the primary and secondary endpoints when comparing lenabasum to placebo, both added to background drug therapy.

    For the primary endpoint, the median American College of Rheumatology Combined Response Index for Systemic Sclerosis (ACR CRISS) scores at Week 52 were 0.887 in the placebo arm and 0.888 in the lenabasum 20 mg twice daily arm. ACR CRISS is a composite endpoint that reflects the probability of patient improvement. The maximum achievable ACR CRISS score is 1.0.

    RESOLVE-1 is the first 52-week, randomized, placebo-controlled Phase 3 trial that tested the efficacy and safety of lenabasum in 365 patients with diffuse cutaneous SSc in a multinational, double-blind, randomized, placebo-controlled study, with dosing of lenabasum at 20 mg twice daily, lenabasum at 5 mg twice daily, or placebo twice daily for 52 weeks. The majority of enrolled patients (84%) were receiving background immunosuppressive drugs, reflecting recent trends in clinical practice.

    Similar proportions of placebo-treated and lenabasum-treated subjects had at least one treatment emergent adverse event (AEs), 86.2% in the placebo arm and 91.7% in the lenabasum 20 mg twice daily arm. Serious AEs occurred in 14.6% of subjects in the control arm and 9.2% of subjects in the lenabasum 20 mg twice daily arm. Severe AEs occurred in 13% of subjects in the control arm and 5.8% of subjects in the lenabasum arm. No subjects receiving lenabasum withdrew from the study because of an AE-related to study drug. Lenabasum treatment was well-tolerated in this study. No evidence of lenabasum-related immunosuppression or new safety signals for lenabasum were observed.

    Further analyses of these data are underway, and once Corbus has a fuller understanding of the data, the Company would like to engage with the FDA to determine potential next steps in this clinical development program. The data will be presented at upcoming medical conferences.

    Yuval Cohen, Ph.D., Chief Executive Officer of Corbus said, "We are surprised and deeply disappointed that the RESOLVE-1 trial did not meet its primary endpoint. I would like to extend my gratitude to the participants in the study and the clinical staff at the study sites, as well as to the Corbus employees, for their hard work and dedication. We now look forward to upcoming topline results from our study of lenabasum in patients with cystic fibrosis."

    Robert Spiera, M.D., Co-Principal Investigator on RESOLVE-1 and Director of the Scleroderma, Vasculitis, and Myositis Program at the Hospital for Special Surgery, Weill Cornell Medical College in New York City said, "I am genuinely surprised by these results. Immunosuppressive drugs, alone or in combination, are increasingly becoming a mainstay of treatment for patients with early diffuse cutaneous SSc. However, the impact of these drugs on disease has not previously been studied systematically and clearly was underappreciated by the community of SSc experts. The high degree of efficacy of background drug therapy in the control arm is well beyond what was expected."

    Professor Christopher Denton, PhD, FRCP, Co-Principal Investigator on RESOLVE-1 and Professor of Experimental Rheumatology at UCL Medical School and Consultant Rheumatologist and Joint Director of the Centre for Rheumatology, Royal Free Hospital, London said, "Whilst the immediate study results are disappointing, RESOLVE-1 provides a rich dataset to understand for the first time how to better target treatments for SSc based upon clinical parameters and concomitant treatment. We are already querying the data to understand the natural history of early diffuse cutaneous SSc and the potential benefits of lenabasum in these subjects. Despite the efficacy of current immunosuppressive treatments in early diffuse cutaneous systemic sclerosis, there is still major unmet need in this patient group. The potential value of a non-immunosuppressive treatment, added-to or used instead of, additional immunosuppressive medications, remains exciting. The safety profile and tolerability of lenabasum is very attractive for use in SSc patients."

    Barbara White, M.D., Chief Medical Officer and Head of Research of Corbus commented, "We will now focus on further analyses of the data to potentially identify groups of patients that may have responded to lenabasum."

    Lenabasum was granted Orphan Drug designation and Fast Track designation for the treatment of SSc from the FDA and Orphan Designation for the treatment of SSc from the European Medicines Agency.

    Lenabasum is currently being evaluated in a Phase 3 DETERMINE study in dermatomyositis, a Phase 2 study in systemic lupus erythematosus, and a Phase 2b study in cystic fibrosis.

    RESOLVE-1 Phase 3 Study Trial Design

    The RESOLVE-1 Phase 3 trial tested the efficacy and safety of lenabasum in people with diffuse cutaneous SSc on background drug therapy, in North America, Europe, Asia, Israel, and Australia. This was a double-blind, randomized, placebo-controlled study, with dosing of lenabasum at 20 mg twice daily, lenabasum at 5 mg twice daily, or placebo twice daily for 52 weeks.

    Three hundred and sixty-five patients were dosed in the study. Baseline characteristics of patients across groups were balanced.

    The primary efficacy outcome for the Phase 3 RESOLVE-1 is a composite clinical trial endpoint known as the ACR CRISS score, assessed at Week 52. The ACR CRISS score was also the primary efficacy endpoint in the preceding Phase 2 study published in Arthritis & Rheumatology in April 2020. The ACR CRISS score is a composite clinical trial endpoint that assesses probability that the subject has improved from baseline and integrates change from baseline in five endpoints selected by experts to be the most relevant indicators of disease improvement in diffuse cutaneous SSc. Secondary efficacy endpoints include three of the five core items of ACR CRISS assessed as change from baseline at Week 52 in mRSS, Health Assessment Questionnaire-Disability index (HAQ-DI), and forced vital capacity (FVC) percent predicted.

    Conference Call details

    Management will host a conference call and webcast presentation today, Tuesday, September 8th, 2020 at 8:30 a.m. ET.

    To participate in the call, please dial (877) 407-3978 (domestic) or (412) 902-0039 (international). The live webcast will be accessible on the Events page of the investors section of the Corbus website, www.corbuspharma.com, and will be archived for 90 days.

    About Lenabasum

    Lenabasum is a rationally designed, oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2), resolves inflammation, and limits fibrosis. CB2 is preferentially expressed on activated immune cells and on fibroblasts, muscle cells, and endothelial cells. In both animal and human studies conducted to date, lenabasum has induced the production of pro-resolving lipid mediators that activate endogenous pathways which resolve inflammation and speed bacterial clearance without immunosuppression. Data from animal models and human clinical studies suggest that lenabasum can reduce expression of genes and proteins involved in inflammation and fibrosis. Lenabasum has demonstrated promising activity in animal models of skin and lung inflammation and fibrosis in systemic sclerosis (SSc). Lenabasum is also active in animal models of lung infection and inflammation in cystic fibrosis and joint inflammation and scarring in rheumatoid arthritis.

    Lenabasum has demonstrated acceptable safety and tolerability profiles in clinical studies to date. Lenabasum treatment was associated with improvement in multiple physician-assessed and patient-reported efficacy outcomes in Phase 2 studies in patients with diffuse cutaneous SSc and patients with dermatomyositis with active skin involvement but not currently active muscle involvement. Lenabasum treatment also was associated with a lower rate of and longer time to pulmonary exacerbations in a Phase 2 cystic fibrosis study.

    Lenabasum is not approved for the treatment of systemic sclerosis, dermatomyositis, cystic fibrosis or systemic lupus erythematosus.

    About Systemic Sclerosis

    Systemic sclerosis, a form of scleroderma, is a chronic, rare, debilitating autoimmune disease affecting approximately 200,000 people in the North America, EU and Japan.1 Systemic sclerosis is considered one of the most life-threatening rheumatic diseases.The disease affects affects the skin and internal organs and is driven by inflammation and fibrosis (scarring of tissue) which can lead to severe damage and failure of multiple organs including the skin, joints, tendons, gastrointestinal tract, lungs, heart, blood vessels and kidneys.3 There is no cure for systemic sclerosis, and current treatments address the clinical manifestations of the disease, not the underlying mechanisms that drive inflammation and fibrosis.4

    About Corbus

    Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of rationally designed, endocannabinoid system-targeting drug candidates. The Company's lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist rationally designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

    Corbus is also developing a pipeline of drug candidates targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, selective cannabinoid receptor type 1 (CB1) inverse agonist designed to be peripherally restricted. Potential indications for CRB-4001 include nonalcoholic steatohepatitis (NASH), among others.

    Lenabasum is not approved for the treatment of systemic sclerosis, dermatomyositis, cystic fibrosis or systemic lupus erythematosus. CRB-4001 is not approved for the treatment of NASH/NAFLD. For more information on Corbus' clinical programs, please visit here.

    Please visit www.CorbusPharma.com and connect with the Company on Twitter, LinkedIn, and Facebook.

    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

    These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Corbus Pharmaceuticals Contacts:

    Ted Jenkins, Senior Director, Investor Relations and Corporate Communications

    Phone: +1 (617) 415-7745

    Email: 

    Lindsey Smith, Director, Investor Relations and Corporate Communications

    Phone: +1 (617) 415-7749

    Email: 

    Christina Tartaglia

    Stern Investor Relations

    Phone: +1 (212) 362-1200

    Email: 

    1.Health Advances, LLC Analysis
      
    2.Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2012;51(6):1017e26
      
    3.Sierra-Sepulveda A, Esquinca-Gonzalez A, Benavides-Suarez SA, Sordo-Lima DE, Caballero-Islas AE, Cabral-Castaneda AR, et al. Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast. Biomed Res Int. 2019;2019:4569826
      
    4.Scleroderma." National Institute of Arthritis and Musculoskeletal and Skin Diseases, U.S. Department of Health and Human Services, 7 September 2020, www.niams.nih.gov/health-topics/scleroderma/advanced#tab-risk.

    Primary Logo

    View Full Article Hide Full Article
    • RESOLVE-1 Phase 3 study of lenabasum for treatment of systemic sclerosis on schedule for topline data this summer
    • Phase 2b study of lenabasum for cystic fibrosis topline results on schedule in Q3 2020
    • Balance sheet strengthened with up to $121M in new capital
    • Company to host conference call and webcast today, August 6, 2020 at 8:30 a.m. ET

    Norwood, MA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today reported financial results for the second quarter of 2020. The Company also provided clinical and corporate updates.

    "We had a busy second quarter as we prepare…

    • RESOLVE-1 Phase 3 study of lenabasum for treatment of systemic sclerosis on schedule for topline data this summer
    • Phase 2b study of lenabasum for cystic fibrosis topline results on schedule in Q3 2020
    • Balance sheet strengthened with up to $121M in new capital
    • Company to host conference call and webcast today, August 6, 2020 at 8:30 a.m. ET

    Norwood, MA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today reported financial results for the second quarter of 2020. The Company also provided clinical and corporate updates.

    "We had a busy second quarter as we prepare for a potentially transformative second half of the year with two expected data readouts, including topline data in our Phase 3 study for systemic sclerosis this summer, followed by our Phase 2b study in cystic fibrosis. We recently announced that we completed sales of $71 million through our ATM program and entered a debt financing agreement for up to $50 million with the first $20 million already received, strengthening our balance sheet and putting us in a solid financial position before topline data," said Yuval Cohen, Ph.D., Chief Executive Officer. "We have also appointed a new board member, Dr. George Golumbeski who brings considerable expertise in corporate and business development. With these recent updates, a strong balance sheet and the critical data readouts now closer than ever, we continue to prepare the groundwork for NDA submission and commercialization following potential FDA approval."

    Recent Corporate Highlights and Achievements:

     Strengthened the Company's balance sheet with up to $121 million in new capital, bolstering its strategic flexibility. The Company received an aggregate of $71 million in gross proceeds from its at-the-market offering coupled with the execution of a $50 million debt financing facility with K2 HealthVentures, a healthcare-focused specialty finance company.
       
     In July, Corbus announced the appointment of George Golumbeski, Ph.D., to its Board of Directors. Dr. Golumbeski brings years of industry experience with a track record of growing companies and advancing innovation. During his corporate career, Dr. Golumbeski held senior leadership positions in business development at Celgene, Novartis, Elan Pharmaceuticals and Schwarz Pharma.
       
     The Company presented at several conferences during the second quarter. In May, Corbus announced the publication of two abstracts at the European League Against Rheumatism ("EULAR") 2020 E-Congress. The first abstract highlighted pre-clinical data suggesting that biologic effects of lenabasum include inhibition of inflammasome activation. The second abstract outlined baseline characteristics of RESOLVE-1 patients in the European Union. Additionally, new data from the lenabasum Phase 2 open-label extension study were presented at the 6th Systemic Sclerosis World E-Congress. Analyses show the American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis ("ACR CRISS") score correlates with improvements from baseline in how patients feel and function. The presentations are available in the Scientific Conferences section of Corbus' website.
       
     In June, the Company announced the publication of baseline patient demographics and disease characteristics in its Phase 2b study of lenabasum in cystic fibrosis. The information was published in an electronic supplement of the Journal of Cystic Fibrosis in connection with the 43rd European Cystic Fibrosis Conference.
       
     Lenabasum recently received Orphan Drug Designation for systemic sclerosis from Japan's PMDA.

    Clinical Program Updates:

    Lenabasum: a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist

     Systemic Sclerosis (SSc) – Last subject visit in RESOLVE-1 Phase 3 study of lenabasum for treatment of systemic sclerosis was announced on May 27. Topline results in SSc, a rare disease and the most lethal of the systemic autoimmune diseases, remain on track for this summer. The multicenter study of 365 patients is randomized 1:1:1 for twice a day dosing of lenabasum at 5 mg, 20 mg, or placebo for 52 weeks, with a 4-week follow up. The primary endpoint is the ACR CRISS score. The open-label extension of this study is active. There are no FDA-approved therapies for the overall treatment of SSc.
       
     Cystic Fibrosis (CF) – Last subject visit in Phase 2b study of lenabasum for CF was announced on June 22. Phase 2b topline results of lenabasum in patients with CF who are at high-risk for recurrent pulmonary exacerbation will follow the RESOLVE-1 data results in the third quarter of 2020. The multicenter study of 425 patients is randomized 1:2:2 for twice a day dosing of lenabasum at 5 mg, 20 mg, or placebo for 28 weeks, with a 4-week follow up. The primary endpoint is event rate of pulmonary exacerbation ("PEx"). Treatment of inflammation to reduce PEx remains a key unmet need in CF.
       
     Dermatomyositis (DM) – Phase 3 "DETERMINE" study in DM, a rare and life-threatening autoimmune disease characterized by skin and muscle inflammation, is ongoing. Last subject's first visit in the double-blind, randomized, placebo controlled, multinational DETERMINE study of lenabasum DM was announced on August 5 with 176 subjects enrolled, with topline data expected in the fourth quarter of 2021. The primary endpoint is ACR / EULAR 2016 Total Improvement Score ("TIS") in Adult Dermatomyositis & Polymyositis. The open-label extension of this study is active. There is significant unmet need for new treatments to achieve disease control in DM because of limited efficacy or toxicity of immunosuppressive agents or refractory disease.
       
     Systemic Lupus Erythematosus (SLE) – Phase 2b study is ongoing. The study, funded and managed by the National Institutes of Health (NIH), is enrolling at 15 sites in the U.S., with enrollment expected to be completed by end of this year or early 2021.

    CRB-4001: a peripherally restricted CB1 inverse agonist and additional candidate compounds

     Nonalcoholic fatty liver disease (NAFLD/NASH) – CRB-4001 is a CB1 inverse agonist which improves metabolic abnormalities and reduces inflammation and fibrosis in non-clinical models of disease. CRB-4001 is undergoing chronic pharmacokinetic studies in primates to measure brain exposure to CRB-4001. Results of these studies are expected this year and will be considered in the design of Phase 1 studies.
       
     Corbus has selected CRB-317 as an additional candidate to add to its pipeline. CRB-317 is a CB2 agonist that has significant potency and selectivity for CB2 and biological activity in animal models of inflammation and fibrosis. IND enabling pre-clinical studies and formulation work are underway. Phase 1 safety testing is expected in 2021.

    Financial Results for Second Quarter Ended June 30, 2020:

    For the quarter ended June 30, 2020, the Company reported a net loss of approximately $38.1 million or a net loss per diluted share of $0.52, compared to net income of approximately $2.2 million or net income per diluted share of $0.03, for the quarter ended June 30, 2019.

    For the quarter ended June 30, 2020 revenue decreased by approximately $28.8 million to $0.3 million, due primarily to revenue for the quarter ended June 30, 2019 including $27 million from the up-front licensing payment received from Kaken Pharmaceuticals in March 2019.

    Operating expenses for the quarter ended June 30, 2020 increased by approximately $11.0 million to $38.4 million. The increase was attributable to clinical studies costs, the costs to manufacture and supply lenabasum for clinical trials, staffing costs, commercialization costs and non-cash stock compensation expense.

    On July 29, 2020, Corbus announced that it received an aggregate of $71 million in gross proceeds from its at-the-market ("ATM") offering coupled with the execution of a $50 million debt financing facility with K2 HealthVentures. Pursuant to the previously disclosed $75 million ATM facility, Corbus sold 9,167,080 shares at a weighted average price of $7.70 per share. Corbus has received the first $20 million tranche from the debt financing facility and has the option to draw $20 million from the second tranche and $10 million from the third tranche, in each case upon achievement of certain regulatory and developmental milestones.

    Corbus expects its cash and cash equivalents on hand of approximately $101 million at July 28, 2020 to fund operations into the third quarter of 2021.



    Conference Call and Webcast Information:

    Corbus management will host a conference call and webcast presentation for investors, analysts and other interested parties today, Thursday, August 6, 2020 at 8:30 a.m. ET.

    To participate in the call, please dial (877) 407-3978 (domestic) or (412) 902-0039 (international). The live webcast will be accessible on the Events page of the Investors section of the Corbus website, www.corbuspharma.com, and will be archived for 90 days.

    About Corbus

    Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of rationally designed, endocannabinoid system-targeting drug candidates. The Company's lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist rationally designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

    Corbus is also developing a pipeline of drug candidates targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, selective cannabinoid receptor type 1 (CB1) inverse agonist designed to be peripherally restricted. Potential indications for CRB-4001 include nonalcoholic steatohepatitis (NASH), among others.

    Lenabasum is not approved for the treatment of systemic sclerosis, dermatomyositis, cystic fibrosis or systemic lupus erythematosus. CRB-4001 is not approved for the treatment of NASH/NAFLD. For more information on Corbus' clinical programs, please visit here.

    Please visit www.CorbusPharma.com and connect with the Company on Twitter, LinkedIn, and Facebook.

    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

    These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Corbus Pharmaceuticals Holdings, Inc.

    Condensed Consolidated Balance Sheets

      June 30,  December 31, 
      2020  2019 
      (unaudited)    
    ASSETS        
    Current assets:        
    Cash and cash equivalents $63,468,769  $31,748,686 
    Customer receivable $5,000,000  $ 
    Stock subscriptions receivable $16,675,971  $ 
    Prepaid expenses and other current assets  2,872,275   3,724,932 
    Contract asset     2,681,065 
    Total current assets  88,017,015   38,154,683 
    Property and equipment, net  4,547,303   5,083,865 
    Operating lease right of use assets  5,539,677   5,818,983 
    Other assets  14,085   84,968 
    Total assets $98,118,080  $49,142,499 
    LIABILITIES AND STOCKHOLDERS' EQUITY        
    Current liabilities:        
    Notes payable $108,936  $752,659 
    Accounts payable  12,697,845   11,091,363 
    Accrued expenses  28,144,144   22,447,939 
    Deferred revenue  270,530    
    Operating lease liabilities, current  873,525   595,745 
    Total current liabilities  42,094,980   34,887,706 
             
    Operating lease liabilities, noncurrent  7,609,221   8,097,228 
    Total liabilities  49,704,201   42,984,934 
    Commitments and Contingencies        
    Stockholders' equity        
    Preferred Stock $0.0001 par value:10,000,000 shares authorized, no shares issued and outstanding at June 30, 2020 and December 31, 2019      
    Common stock, $0.0001 par value; 150,000,000 shares authorized, 80,655,848 and 64,672,893 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively  8,065   6,467 
    Additional paid-in capital  308,991,895   198,975,056 
    Accumulated deficit  (260,586,081)  (192,823,958)
    Total stockholders' equity  48,413,879   6,157,565 
    Total liabilities and stockholders' equity $98,118,080  $49,142,499 



    Corbus Pharmaceuticals Holdings, Inc.


    Condensed Consolidated Statements of Operations

    (Unaudited)

      For the Three Months Ended  For the Six Months Ended 
      June 30,  June 30, 
      2020  2019  2020  2019 
    Revenue from awards and licenses $286,346  $29,094,583  $2,048,405  $30,980,265 
    Operating expenses:                
    Research and development  30,686,071   22,181,409   54,633,937   43,965,113 
    General and administrative  7,738,968   5,207,962   15,438,447   11,832,709 
    Total operating expenses  38,425,039   27,389,371   70,072,384   55,797,822 
    Operating income (loss)  (38,138,693)  1,705,212   (68,023,979)  (24,817,557)
    Other income (expense), net:                
    Interest income, net  12,649   448,717   114,642   783,312 
    Foreign currency exchange gain (loss), net  20,721   (1,276)  147,214   (47,911)
    Other income, net  33,370   447,441   261,856   735,401 
    Net income (loss) $(38,105,323) $2,152,653  $(67,762,123) $(24,082,156)
    Net income (loss) per share, basic $(0.52) $0.03  $(0.95) $(0.38)
    Weighted average number of common shares outstanding, basic  73,885,548   64,546,628   71,578,975   63,119,196 
    Net income (loss) per share, diluted $(0.52) $0.03  $(0.95) $(0.38)
    Weighted average number of common shares outstanding, diluted  73,885,548   68,511,587   71,578,975   63,119,196 

    Corbus Pharmaceuticals Contacts:

    Ted Jenkins, Senior Director, Investor Relations and Corporate Communications

    Phone: +1 (617) 415-7745

    Email:

    Lindsey Smith, Director, Investor Relations and Corporate Communications

    Phone: +1 (617) 415-7749

    Email:

    Christina Tartaglia Stern IR, Inc.

    Phone: +1 (212) 362-1200

    Email:

    Primary Logo

    View Full Article Hide Full Article
    • 12-month, double-blind, placebo-controlled, multi-national study enrolled 176 participants
    • Topline results expected in fourth quarter of 2021
    • Dermatomyositis is a rare, systemic autoimmune disease with characteristic skin and muscle involvement, serious morbidity, and increased mortality

    Norwood, MA, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the completion of subject enrollment in DETERMINE, a Phase 3 study assessing the efficacy and safety of lenabasum for the treatment of dermatomyositis ("DM"). The Company expects to report topline results…

    • 12-month, double-blind, placebo-controlled, multi-national study enrolled 176 participants

    • Topline results expected in fourth quarter of 2021
    • Dermatomyositis is a rare, systemic autoimmune disease with characteristic skin and muscle involvement, serious morbidity, and increased mortality

    Norwood, MA, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the completion of subject enrollment in DETERMINE, a Phase 3 study assessing the efficacy and safety of lenabasum for the treatment of dermatomyositis ("DM"). The Company expects to report topline results from this study in the fourth quarter of 2021.

    "We are grateful to the participants for their commitment and to all of our investigators and their staff for their support of the study and dedication to completing enrollment on time, despite COVID-19," said Barbara White, M.D., Chief Medical Officer of Corbus. "Enrollment exceeded our expectations, which we think speaks to the unmet need of dermatomyositis patients for new treatment options, especially options without some of the toxicities associated with chronic immunosuppression."

    The Company's Phase 3 DETERMINE study has enrolled 176 subjects in the largest, randomized, double-blind, placebo-controlled DM study to date. This study is being conducted in North America, Europe, and Asia. Patients in the study are randomized 2:1:2 to either receive lenabasum 20 mg twice per day, lenabasum 5 mg twice per day or placebo twice per day for 52 weeks with a follow-up period of 4 weeks.

    The primary endpoint of DETERMINE is efficacy of lenabasum compared to placebo as measured by the American College of Rheumatology ("ACR")/ European League Against Rheumatism 2016 Total Improvement Score ("TIS") in myositis at 52 weeks, a weighted composite measure of improvement from baseline in six core set items that include physician directed assessments of Physician Global Activity, Manual Muscle Testing-8, and Extramuscular Global Activity, patient-reported outcomes of Patient Global Activity and Health Assessment Questionnaire, and biomarkers of muscle enzymes.ǂ Multiple secondary outcomes including Cutaneous Dermatomyositis Activity and Severity Index activity score are being evaluated. Additionally, the Company is evaluating the safety and efficacy of lenabasum in an open-label extension of the DETERMINE Phase 3 study. The open-label extension enables participants who complete the double-blind study period to continue to receive lenabasum.

    Lenabasum was granted Orphan Drug Designation for the treatment of dermatomyositis from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

    About Lenabasum

    Lenabasum is a rationally designed, oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2), resolves inflammation, and limits fibrosis. CB2 is preferentially expressed on activated immune cells and on fibroblasts, muscle cells, and endothelial cells. In both animal and human studies conducted to date, lenabasum has induced the production of pro-resolving lipid mediators that activate endogenous pathways which resolve inflammation and speed bacterial clearance without immunosuppression. Data from animal models and human clinical studies suggest that lenabasum can reduce expression of genes and proteins involved in inflammation and fibrosis. Lenabasum has demonstrated promising activity in animal models of skin and lung inflammation and fibrosis in systemic sclerosis (SSc). Lenabasum is also active in animal models of lung infection and inflammation in cystic fibrosis and joint inflammation and scarring in rheumatoid arthritis.

    Lenabasum has demonstrated acceptable safety and tolerability profiles in clinical studies to date. Lenabasum treatment was associated with improvement in multiple physician-assessed and patient-reported efficacy outcomes in Phase 2 studies in patients with diffuse cutaneous SSc and patients with dermatomyositis with active skin involvement but not currently active muscle involvement. Lenabasum treatment also was associated with a lower rate of and longer time to pulmonary exacerbations in a Phase 2 cystic fibrosis study.

    Lenabasum is not approved for the treatment of systemic sclerosis, dermatomyositis, cystic fibrosis or systemic lupus erythematosus.

    About Dermatomyositis

    Dermatomyositis (DM), a form of myositis, is a chronic, rare, inflammatory, clinically heterogenous, life-threatening autoimmune disease affecting approximately 80,000 people in North America, EU and Japan.1 The signs and symptoms of DM reflect multi-organ involvement, which includes distinctive skin rashes usually accompanied by proximal muscle weakness, and can also include pulmonary, cardiac, gastrointestinal, and joint involvement.2 Patients with DM can have recurrent disease flares or chronic progressive disease activity, with increased mortality.3,4 The current mainstay of treatments include FDA-approved systemic glucocorticoids, adrenocorticotropic hormone analogue and off-label use of glucocorticoid-sparing immunosuppressive agents.5,6 There is significant unmet need for new treatments to achieve disease control in DM because of limited efficacy or toxicity of immunosuppressive agents or refractory disease.7,8

    About Corbus

    Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of rationally designed, endocannabinoid system-targeting drug candidates. The Company's lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist rationally designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

    Corbus is also developing a pipeline of drug candidates targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, selective cannabinoid receptor type 1 (CB1) inverse agonist designed to be peripherally restricted. Potential indications for CRB-4001 include nonalcoholic steatohepatitis (NASH), among others. Corbus expects data from its Phase 1 safety study in 2020.

    Lenabasum is not approved for the treatment of systemic sclerosis, dermatomyositis, cystic fibrosis or systemic lupus erythematosus. CRB-4001 is not approved for the treatment of NASH/NAFLD. For more information on Corbus' clinical programs, please visit here.

    Please visit www.CorbusPharma.com and connect with the Company on TwitterLinkedIn, and Facebook.

    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

    These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.



    Corbus Pharmaceuticals Contacts:

    Ted Jenkins, Senior Director, Investor Relations and Corporate Communications

    Phone: +1 (617) 415-7745

    Email: 

    Lindsey Smith, Director, Investor Relations and Corporate Communications

    Phone: +1 (617) 415-7749

    Email: 

    Christina Tartaglia

    Stern Investor Relations

    Phone: +1 (212) 362-1200

    Email: 

    ǂAggarwal R, et al. "2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative." Ann Rheum Dis. 2017 May ; 76(5): 792–801

         1. Health Advances, LLC Analysis

    1. "Dermatomyositis Information Page." National Institute of Neurological Disorders and Stroke, U.S. Department of Health and Human Services, 15 June 2020, www.ninds.nih.gov/Disorders/All-Disorders/Dermatomyositis-Information-Page
    2. Marie, Isabelle. "Morbidity and Mortality in Adult Polymyositis and Dermatomyositis." Current Rheumatology Reports, vol. 14, no. 3, 2012, pp. 275–285., doi:10.1007/s11926-012-0249-3
    1. Schiopu, Elena, et al. "Predictors of Survival in a Cohort of Patients with Polymyositis and Dermatomyositis: Effect of Corticosteroids, Methotrexate and Azathioprine." Arthritis Research & Therapy, vol. 14, no. 1, 2012, doi:10.1186/ar3704

       
    2. FDA label Orapred ODT, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf; accessed 15 June 2020

       
    3. FDA label H.P. Acthar gel, available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/008372s057lbl.pdf; accessed 15 June 2020
    4. Dalakas, Marinos C. "Immunotherapy of Myositis: Issues, Concerns and Future Prospects." Nature Reviews Rheumatology, vol. 6, no. 3, Mar. 2010, pp. 129–137., doi:10.1038/nrrheum.2010.2
    5. DeWane ME, et al. Dermatomyositis: Clinical features and pathogenesis. J Am Acad Dermatol.

    Primary Logo

    View Full Article Hide Full Article
  1. Norwood, MA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at two upcoming conferences.

    The following are the details for the conferences:

    BTIG Virtual Biotechnology Conference 2020

    • Event: Fireside Chat Discussion and Q&A
    • Date and Time: August 10, 2020 at 10:00 AM ET

    Canaccord Genuity 40th Annual Growth Conference

    • Event: Company Presentation and Q&A
    • Date and Time: August 13, 2020 at 3:00 PM ET

    An audio webcast of the presentations will be accessible…

    Norwood, MA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at two upcoming conferences.

    The following are the details for the conferences:

    BTIG Virtual Biotechnology Conference 2020

    • Event: Fireside Chat Discussion and Q&A
    • Date and Time: August 10, 2020 at 10:00 AM ET

    Canaccord Genuity 40th Annual Growth Conference

    • Event: Company Presentation and Q&A
    • Date and Time: August 13, 2020 at 3:00 PM ET

    An audio webcast of the presentations will be accessible on the Events page of the Investors section of the Corbus website, www.corbuspharma.com approximately one hour after each event and will be archived for 90 days following the event.

    About Corbus

    Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of rationally designed, endocannabinoid system-targeting drug candidates. The Company's lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist rationally designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

    Corbus is also developing a pipeline of drug candidates targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, selective cannabinoid receptor type 1 (CB1) inverse agonist designed to be peripherally restricted. Potential indications for CRB-4001 include nonalcoholic steatohepatitis (NASH), among others. Corbus expects data from its Phase 1 safety study in 2020.

    Lenabasum is not approved for the treatment of systemic sclerosis, dermatomyositis, cystic fibrosis or systemic lupus erythematosus. CRB-4001 is not approved for the treatment of NASH/NAFLD. For more information on Corbus' clinical programs, please visit here.

    For more information, please visit www.CorbusPharma.com and connect with the Company on TwitterLinkedIn, and Facebook.

    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

    These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Corbus Pharmaceuticals Contacts:

    Ted Jenkins, Senior Director, Investor Relations and Corporate Communications

    Phone: +1 (617) 415-7745

    Email: 

    Lindsey Smith, Director, Investor Relations and Corporate Communications

    Phone: +1 (617) 415-7749

    Email: 

    Christina Tartaglia

    Stern IR, Inc.

    Phone: +1 (212) 362-1200

    Email: 

    Primary Logo

    View Full Article Hide Full Article
    • Management to host conference call and webcast on Thursday, August 6 at 8:30 a.m. ET

    Norwood, MA, July 30, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it will report its second quarter financial results on Thursday, August 6. Corbus management will host a conference call and live audio webcast to discuss operational and financial results at 8:30 a.m. ET that same day.

    The call will be led by Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. He will be joined by additional members of the Corbus management team. Interested participants and…

    • Management to host conference call and webcast on Thursday, August 6 at 8:30 a.m. ET

    Norwood, MA, July 30, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it will report its second quarter financial results on Thursday, August 6. Corbus management will host a conference call and live audio webcast to discuss operational and financial results at 8:30 a.m. ET that same day.

    The call will be led by Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. He will be joined by additional members of the Corbus management team. Interested participants and investors may access the conference call by dialing (877) 407-3978 (domestic) or (412) 902-0039 (international). The live webcast will be accessible on the Events page of the Investors section of the Corbus website, www.corbuspharma.com and will be archived for 90 days following the event.

    About Corbus

    Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of rationally designed, endocannabinoid system-targeting drug candidates. The Company's lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist rationally designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

    Corbus is also developing a pipeline of drug candidates targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, selective cannabinoid receptor type 1 (CB1) inverse agonist designed to be peripherally restricted. Potential indications for CRB-4001 include nonalcoholic steatohepatitis (NASH), among others. Corbus expects data from its Phase 1 safety study in 2020.

    Lenabasum is not approved for the treatment of systemic sclerosis, dermatomyositis, cystic fibrosis or systemic lupus erythematosus. CRB-4001 is not approved for the treatment of NASH/NAFLD. For more information on Corbus' clinical programs, please visit here.

    For more information, please visit www.CorbusPharma.com and connect with the Company on TwitterLinkedIn, and Facebook.

    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

    These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Corbus Pharmaceuticals Contacts:

    Ted Jenkins, Senior Director, Investor Relations and Corporate Communications

    Phone: +1 (617) 415-7745

    Email: 

    Lindsey Smith, Director, Investor Relations and Corporate Communications

    Phone: +1 (617) 415-7749

    Email: 

    Christina Tartaglia

    Stern IR, Inc.

    Phone: +1 (212) 362-1200

    Email: 

    Primary Logo

    View Full Article Hide Full Article
View All Corbus Pharmaceuticals Holdings Inc. News